Asia Pacific Metastatic Cancer Drugs Market

Historic Data: 2019-2020   |   Base Year: 2021   |   Forecast Period: 2022-2028

Analysis By Cancer Type (Breast Cancer, Lung Cancer, Liver Cancer, Hematological Cancer, Brain Cancer, Prostate Cancer, Pancreatic Cancer, and Others), Route of Administration (Intravenous and Intramuscular), Drug Class (HER2 Inhibitors, Immune Checkpoint Inhibitors, PARP Inhibitors, Kinase Inhibitors, and Others), Product (Branded, Generics, and Biosimilars), and End User (Hospital, Specialty Clinic, and Others)

No. of Pages: 181
Report Code: BMIRE00025358
Category: Life Sciences
Asia Pacific Metastatic Cancer Drugs Market
Free Sample Buy Now

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Data Triangulation and Validation

4. Asia Pacific Metastatic Cancer Drugs Market Landscape

4.1 Overview
4.3 Ecosystem Analysis
  • 4.3.1 List of Vendors in the Value Chain

5. Asia Pacific Metastatic Cancer Drugs Market – Key Market Dynamics

5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints

6. Asia Pacific Metastatic Cancer Drugs Market Regional Analysis

6.2 Asia Pacific Metastatic Cancer Drugs Market Revenue 2019-2028 (US$ Million)
6.3 Asia Pacific Metastatic Cancer Drugs Market Forecast Analysis

7. Asia Pacific Metastatic Cancer Drugs Market Analysis – by Cancer Type

7.1 Breast Cancer
  • 7.1.1 Overview
  • 7.1.2 Breast Cancer: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Lung Cancer
  • 7.2.1 Overview
  • 7.2.2 Lung Cancer: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Liver Cancer
  • 7.3.1 Overview
  • 7.3.2 Liver Cancer: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.4 Hematological Cancer
  • 7.4.1 Overview
  • 7.4.2 Hematological Cancer: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.5 Brain Cancer
  • 7.5.1 Overview
  • 7.5.2 Brain Cancer: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.6 Prostate Cancer
  • 7.6.1 Overview
  • 7.6.2 Prostate Cancer: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.7 Pancreatic Cancer
  • 7.7.1 Overview
  • 7.7.2 Pancreatic Cancer: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

8. Asia Pacific Metastatic Cancer Drugs Market Analysis – by Route of Administration

8.1 Intravenous and Intramuscular
  • 8.1.1 Overview
  • 8.1.2 Intravenous and Intramuscular: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

9. Asia Pacific Metastatic Cancer Drugs Market Analysis – by Drug Class

9.1 HER2 Inhibitors
  • 9.1.1 Overview
  • 9.1.2 HER2 Inhibitors: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.2 Immune Checkpoint Inhibitors
  • 9.2.1 Overview
  • 9.2.2 Immune Checkpoint Inhibitors: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.3 PARP Inhibitors
  • 9.3.1 Overview
  • 9.3.2 PARP Inhibitors: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
9.4 Kinase Inhibitors
  • 9.4.1 Overview
  • 9.4.2 Kinase Inhibitors: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

10. Asia Pacific Metastatic Cancer Drugs Market Analysis – by Product

10.1 Branded
  • 10.1.1 Overview
  • 10.1.2 Branded: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.2 Generics
  • 10.2.1 Overview
  • 10.2.2 Generics: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)
10.3 Biosimilars
  • 10.3.1 Overview
  • 10.3.2 Biosimilars: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast, 2019-2028 (US$ Million)

11. Asia Pacific Metastatic Cancer Drugs Market – Asia-Pacific Analysis

11.1 Overview

11.2 Asia-Pacific
  • 11.2.1 Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 11.2.1.1 Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast Analysis – by Country
  • 11.2.1.1 China: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.1.1 China: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 11.2.1.1.2 China: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 11.2.1.1.3 China: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Drug Class
    • 11.2.1.1.4 China: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Product
  • 11.2.1.2 India: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.2.1 India: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 11.2.1.2.2 India: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 11.2.1.2.3 India: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Drug Class
    • 11.2.1.2.4 India: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Product
  • 11.2.1.3 Japan: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.3.1 Japan: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 11.2.1.3.2 Japan: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 11.2.1.3.3 Japan: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Drug Class
    • 11.2.1.3.4 Japan: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Product
  • 11.2.1.4 Australia: Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.4.1 Australia: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 11.2.1.4.2 Australia: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 11.2.1.4.3 Australia: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Drug Class
    • 11.2.1.4.4 Australia: Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Product
  • 11.2.1.5 Rest of Asia-Pacific : Asia Pacific Metastatic Cancer Drugs Market – Revenue and Forecast to 2028 (US$ Million)
    • 11.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Cancer Type
    • 11.2.1.5.2 Rest of Asia-Pacific : Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Route of Administration
    • 11.2.1.5.3 Rest of Asia-Pacific : Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Drug Class
    • 11.2.1.5.4 Rest of Asia-Pacific : Asia Pacific Metastatic Cancer Drugs Market Breakdown, by Product

12. Competitive Landscape

12.1 Heat Map Analysis
12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments

14. Company Profiles

14.1 AbbVie Inc.
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
14.2 Amgen Inc.
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
14.3 Bristol-Myers Squibb Company
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
  • 14.3.6 Key Developments
14.4 F. HOFFMANN-LA ROCHE LTD.
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
14.5 Novartis AG
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
14.6 Astrazeneca
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
14.7 Eli Lilly and Company
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments
14.8 MERCK KGaA
  • 14.8.1 Key Facts
  • 14.8.2 Business Description
  • 14.8.3 Products and Services
  • 14.8.4 Financial Overview
  • 14.8.5 SWOT Analysis
  • 14.8.6 Key Developments
14.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
  • 14.9.1 Key Facts
  • 14.9.2 Business Description
  • 14.9.3 Products and Services
  • 14.9.4 Financial Overview
  • 14.9.5 SWOT Analysis
  • 14.9.6 Key Developments
14.10 Johnson and Johnson Services, Inc.
  • 14.10.1 Key Facts
  • 14.10.2 Business Description
  • 14.10.3 Products and Services
  • 14.10.4 Financial Overview
  • 14.10.5 SWOT Analysis
  • 14.10.6 Key Developments

15. Appendix

15.1 About Business Market Insights
15.2 List of Abbreviations

The List of Companies - Asia Pacific Metastatic Cancer Drugs Market

  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • F. HOFFMANN-LA ROCHE LTD.
  • Novartis AG
  • Astrazeneca
  • Eli Lilly and Company
  • MERCK KGaA
  • Pfizer Inc. (Arena Pharmaceutical GmbH)
  • Johnson and Johnson Services, Inc.

    • Available Report Formats

    pdf-format excel-format pptx-format
    Buy Now
    Customization Form

    Please tell us your area of interest
    (Market Segments/ Regions and Countries/ Companies)